Agree about the difficulty and limited competition. My point was more PLX seems to be modeling existing LSD (which makes some sense since they are the bigger ones) but as you and genisi pointed out I don't see people switching in large percentages unless forced to or a better alternative exists. So I am thinking that PLX may try to compete on price.
I agree Amicus, BMRN, PTC and even the oral Genzyme program have a way to go on the enhanced programs. My point was there are already other things in the clinic and I didn't even mention gene therapy :-).
I actually took the delay (I figure it'll be close to a year and could even be much worse) as a bigger setback then the market did. It gives Genzyme time to get their Manufacturing in order and get their oral product that much closer to the market. Not sure how close they are in the EU submission but maybe that goes through smoothly? They did say didn't get the 180 day questions yet so that has a ways to go still (considering clock stops for them to answer). Also I thought I heard PLX say they needed to meet with the FDA to get clarification on question regarding Manufacturing I took this as a potentially more serious concern maybe an innocent remark but one can never be sure.
News 
Market Data 
Discover 
AI
